Swiss National Bank Increases Stock Position in Solventum Co. (NYSE:SOLV)

Swiss National Bank grew its position in Solventum Co. (NYSE:SOLV) by 0.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 435,709 shares of the company’s stock after acquiring an additional 3,000 shares during the period. Swiss National Bank owned about 0.25% of Solventum worth $30,378,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Deseret Mutual Benefit Administrators purchased a new position in Solventum during the second quarter worth approximately $25,000. Hollencrest Capital Management purchased a new position in shares of Solventum during the 2nd quarter valued at approximately $25,000. Partnership Wealth Management LLC acquired a new stake in Solventum in the 2nd quarter valued at $26,000. Richard W. Paul & Associates LLC acquired a new position in Solventum during the second quarter worth $26,000. Finally, Family Firm Inc. purchased a new position in Solventum during the second quarter valued at $26,000.

Solventum Price Performance

SOLV opened at $68.39 on Thursday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The business’s 50 day moving average price is $70.49 and its 200 day moving average price is $62.26.

Analyst Ratings Changes

A number of equities analysts have commented on SOLV shares. BTIG Research began coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating for the company. Piper Sandler lifted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Morgan Stanley upped their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Finally, The Goldman Sachs Group increased their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Solventum presently has an average rating of “Hold” and an average target price of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.